Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with... Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease. Mehr anzeigen
Equillium retains rights to itolizumab following substantial funding from Ono partnership Evaluating accelerating Phase 3 EQUATOR study in aGVHD to completion in Q1 2025 Phase 2 ulcerative...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory...
Dual and synergistic signaling of IL-15 and IL-21 robustly augments NK and CD8 T cell responses Highlights importance of dual inhibition or activation for therapeutic approaches Equillium Inc...
Ono Pharmaceutical makes strategic business decision to allow itolizumab option to expire Equillium evaluating accelerating completion of Phase 3 EQUATOR study in aGVHD to Q1 2025 Phase 2...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.08 | -10.3896103896 | 0.77 | 0.8898 | 0.6637 | 209249 | 0.75638774 | CS |
| 4 | -0.42 | -37.8378378378 | 1.11 | 1.5 | 0.6637 | 307061 | 0.9371643 | CS |
| 12 | -0.47 | -40.5172413793 | 1.16 | 1.5 | 0.6637 | 192235 | 0.95222469 | CS |
| 26 | -0.88 | -56.050955414 | 1.57 | 1.61 | 0.6006 | 262904 | 0.95135843 | CS |
| 52 | 0.171 | 32.9479768786 | 0.519 | 3.25 | 0.478899 | 258037 | 1.30415681 | CS |
| 156 | -4.52 | -86.7562380038 | 5.21 | 5.63 | 0.45 | 165833 | 1.40676291 | CS |
| 260 | -2.96 | -81.095890411 | 3.65 | 30.2 | 0.45 | 360952 | 10.62829044 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
